Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh (950210) Stock Statistics & Valuation Metrics

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has a market cap or net worth of KRW 241.59B. The enterprise value is KRW 504.06B.

Market Cap

KRW 241.59B

Enterprise Value

KRW 504.06B

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has 60,096,153 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

60,096,153

Owned by Insiders

―

Owned by Institutions

0.03%

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -13.80%.

Return on Equity (ROE)

-0.21

Return on Assets (ROA)

-0.12

Return on Invested Capital (ROIC)

-13.80%

Return on Capital Employed (ROCE)

-0.16

Revenue Per Employee

407.25M

Profits Per Employee

-1.43B

Employee Count

64

Asset Turnover

0.04

Inventory Turnover

1.29

The current PE Ratio of Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh is -2.61. Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh’s PEG ratio is 0.01.

PE Ratio

-2.61

PS Ratio

9.27

PB Ratio

0.56

Price to FCF

-3.88

Price to Operating Cash Flow

-4.33

PEG Ratio

0.01

In the last 12 months, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh had revenue of 26.06B and earned -91.47B in profits. Earnings per share was -1522.10.

Revenue

26.06B

Gross Profit

-16.36B

Operating Income

-93.58B

Pretax Income

-123.01B

Net Income

-91.47B

EBITDA

-60.84B

Earnings Per Share (EPS)

-1522.10

In the last 12 months, operating cash flow was -55.80B and capital expenditures -6.43B, giving a free cash flow of -62.23B billion.

Operating Cash Flow

-55.80B

Free Cash Flow

-62.23B

Free Cash Flow per Share

-1035.44

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-25.76%

Earnings Yield

-38.36%

Beta

-0.01

52-Week Price Change

-68.30%

50-Day Moving Average

5899.10

200-Day Moving Average

7759.52

Relative Strength Index (RSI)

14.56

Average Volume (3m)

49.70K

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh upcoming earnings date is Nov 26, 2026, TBA (Not Confirmed).

Last Earnings Date

Sep 22, 2026

Next Earnings Date

Nov 26, 2026

Ex-Dividend Date

―

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh as a current ratio of 0.75, with Debt / Equity ratio of 24.44%

Current Ratio

0.75

Quick Ratio

0.52

Debt to Market Cap

0.27

Net Debt to EBITDA

-1.47

Interest Coverage Ratio

-13.52

In the past 12 months, Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has paid -151.56M in taxes.

Income Tax

-151.56M

Effective Tax Rate

0.00

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh EV to EBITDA ratio is -5.45, with an EV/FCF ratio of -5.32.

EV to Sales

12.70

EV to EBITDA

-5.45

EV to Free Cash Flow

-5.32

EV to Operating Cash Flow

-5.93

Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh has KRW 63.01B in cash and marketable securities with KRW 106.11B in debt, giving a net cash position of -KRW 43.10B billion.

Cash & Marketable Securities

KRW 63.01B

Total Debt

KRW 106.11B

Net Cash

-KRW 43.10B

Net Cash Per Share

-KRW 717.24

Tangible Book Value Per Share

KRW 5,094.01

Gross margin is -118.21%, with operating margin of -359.06%, and net profit margin of -355.52%.

Gross Margin

-118.21%

Operating Margin

-359.06%

Pretax Margin

-471.95%

Net Profit Margin

-355.52%

EBITDA Margin

-233.13%

EBIT Margin

-358.97%

The average price target for Prestige BioPharma Limited Korean Deposit Receipt Repr 1/5 Sh is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target

―

Price Target Upside

―

Analyst Consensus

―

Analyst Count

―

Revenue Growth Forecast

84.72%

EPS Growth Forecast

-480.97%

Smart Score

―

AI Score

45